In conclusion, high baseline plasma AREG levels predicted worse PFS in patients with RAS/BRAF wild-type metastatic colorectal cancer treated with palliative first-line cetuximab plus FOLFIRI chemotherapy, but not with non-EGFR-directed second-line treatment. The gene discussed is EGFR; the disease is metastatic colorectal cancer.